image credit- shutterstock
Mumbai-based GOQii, a leading smart preventive healthcare company, has joined forces with Acrannolife Genomics, a pioneer in precision diagnostics in Chennai, to launch the GrafCare Programme. This ground breaking initiative leverages advanced genomic diagnostics, artificial intelligence (AI), and personalised health monitoring to redefine post-transplant care for organ recipients in India.
To address the unique challenges faced by transplant recipients, the GrafCare Programme combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. This powerful integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life.
Acrannolife’s US-patented Trunome test is a non invasive blood test that identifies early signs of organ rejection or infection. Powered by advanced genomic research and AI, the test provides clinicians with precise, actionable insights to intervene before complications escalate.
Patients receive a GOQii Smart Vital Device, which tracks vital parameters such as heart rate, blood pressure, and oxygen levels in real time. AI-driven predictive analytics assess patient data to generate early alerts and personalised recommendations, enabling proactive care.
With over 20,000 transplants performed annually in India and a growing global demand for post-transplant solutions, the GrafCare Program is poised to redefine healthcare delivery.
